76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
CSL Ltd
Open
SectorIndustrials
238.61 -0.37
Overview
Share price change
24h
Min
237.71
Max
241.23
Income | 1.3B 2B |
|---|---|
Sales | -5.7B 2.5B |
P/E Sector Avg | 28.556 36.969 |
EPS | 1.831 |
Dividend yield | 1.77 |
Profit margin | 24.437 |
Employees | 32,698 |
EBITDA | -2.4B 858M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +29.56% upside |
Dividend yield Sector Avg | 1.77% 2.72% |
|---|---|
Next Earnings | 12 Aug 2025 |
Market Cap | -8.5B 116B |
|---|---|
Previous open | 238.98 |
Previous close | 238.61 |
CSL Ltd Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
CSL Ltd Forecast
Price Target
By TipRanks
29.56% upside
12 Months Forecast
Average 312.519 AUD 29.56%
High 330 AUD
Low 303 AUD
Based on 8 Wall Street analysts offering 12 month price targets forCSL Ltd - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About CSL Ltd
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.
